Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Access to therapeutic innovation, ANSM perpetuates its accelerated authorization circuits for clinical trials of so-called “fast-track” drugs

ANSM has decided to perpetuate the two accelerated clinical trial authorization devices (Fast Track)

admin 21 October 2019 All news
  • ← What is Pharmacovigilance?
  • First vaccine to protect against Ebola →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • A common EU approach to data transparency in medicine regulation
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 November 2024
  • European regulation on clinical trials for medicinal products: The end of the transition period
Copyright © 2018 - Pharmya - Legal terms - Quality Policy